Nexavar in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer. Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction. An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider permanent discontinuation of Nexavar. continue reading below »
Treatment recommendations are based on a high level of evidence and uniform consensus.1
Visit www.nccn.org to view the recommendations.Read more about:
Reference: 1. The NCCN Clinical Practice Guidelines in Oncology™. Hepatobiliary Cancers (Version 2.2012). Fort Washington, PA: National Comprehensive Cancer Network; 2011. http:www.nccn.org. Accessed October 19, 2012.